No. 5 · Finance · 18 November 2026

Poultry was Elanco's only falling line in 3Q26

Elanco's third quarter revenue rose 11% as pet health grew 14% and cattle 17%. Poultry was the only species to fall, down 7% on lower volumes, and its growth has slowed since the first quarter of 2026.

Elanco third quarter 2026: revenue, adjusted EBITDA and adjusted net income against 3Q25, and revenue by category with change vs 3Q25; pet health up 14%, cattle up 17%, poultry down 7%, swine up 5%

Tap the exhibit to open it at full size.

Elanco reported third quarter revenue of US$1,265 m, 11% above 3Q25. Stripping out currency, the April acquisition of AHV and royalty income it has already sold, growth was 9%: 4 points from higher prices and 5 from selling more product. Profit rose faster than sales. Adjusted EBITDA, Elanco's measure of operating profit before depreciation, amortisation and special charges, grew 23% to US$243 m, and net income moved from a loss of US$34 m to a profit of US$18 m.

Pets drove the quarter. Pet health revenue rose 14% to US$608 m, on 5% higher prices and 9% higher volumes. The growth came from new products. Zenrelia (ilunocitinib), a JAK inhibitor for allergic itch in dogs, gained 7 points of United States share in its class. Credelio Quattro, a combination parasiticide covering fleas, ticks, heartworm and intestinal worms, overtook the Seresto collar as Elanco's largest pet brand in the United States. Pet health is now 48% of Elanco revenue.

Cattle grew fastest. Cattle revenue rose 17% to US$339 m, or 11% excluding currency and AHV, the Dutch farm animal health company Elanco bought in April. Elanco credits Rumensin (monensin), the ionophore fed to beef and dairy cattle, and notes that customer buying patterns played a part.

Poultry was the exception. Poultry revenue fell 7% to US$201 m, the only species to decline, on lower volumes. On the earnings call, Elanco pointed to lower poultry vaccine sales in the United States; international poultry also fell, with no reason given. Elanco did not say which vaccines, customers or markets. Over nine months poultry revenue is still US$654 m, 5% above the same period of 2025, or 3% excluding currency. Poultry is 16% of Elanco revenue and a third of its farm animal business.

Bar chart of Elanco poultry revenue by quarter, 1Q24 to 3Q26: a peak of 237 in 4Q25, then 230, 223 and 201 in 2026, with growth against the same quarter of 2025 of +22%, +4% and −7%

Poultry growth has slowed since the first quarter of 2026. Revenue peaked at US$237 m in 4Q25 and has been lower in each quarter since. Fourth quarters were the strongest of both 2024 and 2025, so the fair comparison is with the same quarter a year earlier, against which growth went from 22% in 1Q26 to 4% in 2Q26 and to −7% in 3Q26.

Margins widened. Adjusted gross margin, the share of revenue left after the cost of making the products, rose 3.0 points to 56.1%, on higher prices and a richer mix of pet and cattle products. Net debt fell to 2.9 times a year of adjusted EBITDA, from 3.6 times at the end of 2025, which Elanco says gives it more flexibility in how it uses its cash.

Guidance. Elanco raised its 2026 revenue guidance to US$5.155 bn to US$5.18 bn (previously US$5.09 bn to US$5.14 bn), about 8% growth excluding currency and acquisitions, and its adjusted EBITDA guidance to US$1.05 bn to US$1.065 bn. It expects farm animal growth to moderate in the fourth quarter against strong comparisons from 2025.

The Ulnus read

Elanco calls poultry the steadiest part of its farm animal business and expects it to lead, with dairy, in 2027. In the fourth quarter, poultry revenue has to beat US$237 m, its 4Q25 peak, to grow against the same quarter of 2025.

Elanco expects animal protein consumption to keep accelerating, yet its poultry sales shrank in the quarter.

Source: Elanco, Third Quarter 2026 Results, Form 10-Q and earnings call (6 November 2026); quarterly results since May 2025. Ulnus analysis.

About this analysis. Ulnus may use artificial intelligence tools to extract and process source data, run calculations and draft commentary. All such work is directed, reviewed and approved by Ulnus, and every figure is checked against the cited source before publication. The analysis and conclusions are those of Ulnus. This content is provided for information only and does not constitute investment advice.